Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
The company found that Dr. Sykes has held numerous positions at UC Davis for more than 20 years including Chief Veterinary Medical Officer / Associate Dean of Veterinary Medical Center Operations, Director of Small Animal Clinical Services, and Infection Control Officer for the Veterinary Medical Teaching Hospital
LexaGene Holdings Inc announced that Dr. Jane Sykes, Executive Director of Innovation and Entrepreneurship, School of Veterinary Medicine, University of California, Davis (UC Davis), has joined the company’s board of directors.
The company found that Dr. Sykes has held numerous positions at UC Davis for more than 20 years including Chief Veterinary Medical Officer / Associate Dean of Veterinary Medical Center Operations, Director of Small Animal Clinical Services, and Infection Control Officer for the Veterinary Medical Teaching Hospital.
In a statement, Dr. Jack Regan, CEO and Founder of LexaGene: “Dr. Sykes is an entrepreneurial leader whose education and focus on animal care, including infectious diseases, will be a tremendous asset to our business, our science and our future. Her deep experience, academic acumen, and veterinary perspective make her the perfect LexaGene champion. She will be an excellent resource and partner to our company as we continue to grow our business and make progress in introducing diagnostic PCR testing in the clinic to veterinary practices across the country. “
READ: LexaGene Holdings Announces Expansion of Biopharma Contamination Panel by Adding Biothreat Test to Its MiQLab System
Dr. Sykes said, “I am excited to join LexaGene’s board of directors. I share Dr. Regan’s beliefs and passion for point-of-care PCR testing and a passion for improving pet care as we introduce the MiQLab to the veterinary market. I am very excited to serve on the LexaGene board of directors and to work with the other board members to improve shareholder value. “
She was also an associate editor of the Journal of Veterinary Internal Medicine and is currently serving as the future president of the American College of Veterinary Medicine (ACVIM). Dr. Sykes received her degree in veterinary medicine from the University of Melbourne and her MBA from the University of Georgia. In 2006 she founded the International Society for Companion Animal Infectious Diseases (ISCAID).
The term of office of Dr. Sykes began serving on the board on November 8, 2021 when she joined Dr. Manohar replaced Furtado, who has taken on a new role for a company that takes up 100% of his time.
Dr. Regan commented, “I am extremely grateful to Manohar’s mentoring and contributions to our board of directors and LexaGene. Manohar was an excellent board member and I wish him every success in his new endeavor. “
On November 10, 2021, under the company’s Omnibus stock option plan, LexaGene announced that its board member, Dr. Sykes has granted 100,000 non-statutory stock options (NSOs) to purchase common stock in the company at an exercise price of C $ 0.66 each. The company said 10% of these stock options vest on the grant date and 15% every six months thereafter. The NSOs expire on November 11th, 2031.
In addition, the company announced that the board of directors, Dr. Sykes has granted 100,000 Restricted Share Units (RSUs). The company announced that 10% of these RSUs were closed on Jan.
LexaGene is a molecular diagnostic company providing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for rapid on-site testing in veterinary diagnostics, food safety and for use in open markets such as clinical research, agricultural testing and. develops bio-defense. End users only need to take a sample, load it into the device with a sample prep cartridge, enter the sample ID and press Go.
The MiQLab system offers excellent sensitivity, specificity and detection breadth and can deliver results in around two hours. The unique open access feature is designed for custom testing, so end users can load their own real-time PCR assays onto the device to achieve any genetic target of interest.
Contact the author at jon.hopkins@proactiveinvestors.com
